The efficiency of interferon beta (IFNβ)-based drugs is considerably limited due to their undesirable properties, especially high immunogenicity. In this study, for the first time we investigated the impact of a computationally designed peptide mimetic of IFNβ, called MSPEP27, in the animal model of MS.
Introduction
Multiple sclerosis (MS) is a highly varied and unpredictable autoimmune disease which is speculated to attack the myelin proteins in the central nervous system (CNS). One of the most important hallmarks of the MS process is that peripherally activated inflammatory cells can pass across the blood-brain barrier (BBB) leading to demyelination within the CNS (Pinheiro et al., 2016) . Numerous studies have been undertaken to understand the key inflammatory mediators and neurodegenerative mechanisms that underlie the relapsing, and eventually progressive phase of the disease. Consequently, there are several natural-and synthetic-based treatment strategies which are widely used to alleviate the exacerbations of MS (Wingerchuk and Carter, 2014; Alexander, 2016) . Several interferon beta (IFNβ)-based formulations such as Avonex, Betaseron, Plegridy and Rebif have been shown to attenuate the MS signs and are used as first-line treatment for relapsing-remitting multiple sclerosis (RRMS) (Limmroth et al., 2011) . However, IFNβ therapy is substantially associated with a number of adverse side effects including flu-like symptoms, inconsistencies in patient laboratory analyses, menstrual disorders, and increased spasticity (Walther and Hohlfeld, 1999) . Moreover, similar to other clinically available protein-based drugs, IFNβ has a range of drawbacks including the high number of antigenic regions, its high cost and susceptibility to proteolytic degeneration (van Beers et al., 2010; Reuss, 2013) . Peptides can be assumed as suitable alternatives of IFNβ for treatment of MS. These compounds have several unique physicochemical properties that make them attractive in medical interventions (Poorebrahim et al., 2017; Iman et al., 2016) .
In a previous study, Sato and colleagues isolated a 15-mer peptide (SVQARWEAAFDLDLY) mimetic of IFNβ, named SYR6, using phagedisplay screening which could efficiently bind to type I IFN receptor (IFNAR1) in a concentration-dependent manner (Sato and Sone, 2003) . This peptide could effectively elicit antiviral activity in vitro, even in the presence of neutralizing monoclonal antibodies against interferon types. However, the authors reported that the deduced amino acid sequence of SYR6 had no similarity to the primary sequence of IFNβ. In a separate study, the structural basis of IFNβ-IFNAR1 interactions was studied using crystallography (de Weerd et al., 2013) . Interferons are known to initiate specific signals via formation of the heterodimeric IFNAR1-IFNAR2 complex. However, the authors of this study found that IFNβ was able to induce intracellular signals through binding with IFNAR1, independent of IFNAR2. Thus, IFNβ can be considered as a promising candidate for designing mimetic peptides in MS therapy because there is no apparent need to target both IFNAR1 and IFNAR2, simultaneously. Here, we have rationally designed and improved a peptide mimetic of IFNβ, designated MSPEP27, based on the evolutionary, structural and dynamic information of the IFNβ-IFNAR1 complex as well as literature-based data. The peptide was capable of significantly reducing brain dysfunction in an experimental autoimmune encephalomyelitis (EAE) mouse model of MS by down-regulating the production of inflammatory mediators.
Methods

Rational design of mimetic peptide in silico
Evolutionary and functional studies
In order to identify conserved residues in the primary sequence of IFNβ, a multiple sequence alignment was performed using the default parameters of the Clustal W program (Larkin et al., 2007) . First, the amino acid sequences of IFNβ in human, mouse and rat were obtained from UniProt databank (http://www.uniprot.org/). Subsequently, MSA was performed and the aligned sequences were visualized using the Jalview program (Waterhouse et al., 2009) . In parallel, the ConSurf server was used to predict the putative functional residues involved in IFNβ activity (Glaser et al., 2003) . This algorithm identifies the patches of highly conserved (or occasionally variable) residues of a given three dimensional (3D) structure which are generally associated with an important biological function.
Preparation of 3D structures of IFNβ and IFNAR1
The 3D structure of human IFNβ (PDB ID: 1AU1, Resolution: 2.2 Å) and IFNAR1 (PDB ID: 3S98, Resolution: 1.9 Å) were obtained from Protein Data Bank (PDB) (http://www.rcsb.org/pdb/home/home.do). To gain insights into the IFNβ-IFNAR1 mode of interaction, the NMR structure of murine Ifnβ in complex with Ifnar1 was downloaded from PDB (PDB ID: 3WCY) databank. For structural alignment analyses, the unbound structure of murine Ifnβ (PDB ID: 1WU3, Resolution: 2.15 Å) was also provided.
Structural alignment of IFNβ/Ifnβ and IFNAR1/Ifnar1
After evaluating the mode of interaction for the murine Ifnβ-Ifnar1 complex, a structural alignment was applied to identify the structurally conserved residues between the human and murine proteins. The unbound structures of human IFNβ and murine Ifnβ were structurally aligned using SuperPose and TM-align servers (Maiti et al., 2004; Zhang and Skolnick, 2005) . A structural alignment was also carried out between human IFNAR1 and murine Ifnar1 utilizing the tools above. However, the unbound structure of murine Ifnar1 was not available in PDB databank, and therefore the 3WCY pdb file was retrieved using PyMOL software (DeLano, 2002) .
Molecular docking studies
Molecular docking studies were applied utilizing two popular web tools, ClusPro and HADDOCK (Comeau et al., 2004; De Vries et al., 2010) . The ligand-binding site of human IFNAR1/2 was determined according to the study of Chill and colleagues (Chill et al., 2003) . The IFNAR-binding site of human IFNβ was also predicted according to the receptor-binding site of murine Ifnar1. Consequently, both blind and high-resolution docking runs were separately performed. Finally, the protein complexes with lowest binding energy were chosen and visualized using LigPlot + software to understand the functionally interacting residues of IFNβ and IFNAR1 (Laskowski and Swindells, 2011) . Prior to docking, 3D structures of the peptides were predicted using the PEP-FOLD server (Maupetit et al., 2009 ). The solution structure of SYR6 peptide was obtained from PDB database (PDB ID: 1ID7).
Peptide library construction and improvement of physicochemical properties
The physicochemical properties of the initial peptide (MLQNIFAIFRQDSSSTGWNETIVENLL) were improved via several possible amino acid substitutions. A peptide library was then constructed using Rosetta backrub with sequence tolerance protocols implemented in the Rosetta3.5 software and the most tolerated peptide sequence was determined among hundreds of generated peptides (Lauck et al., 2010) . It should be noted that critical functional residues involved in interaction with IFNAR1 were not altered. Physicochemical features including molecular weight, theoretical pI, net charge at pH 7, instability index, grand average of hydropathicity (GRAVY), number of aggregation hot spots, number of antigenic regions, half-life, water solubility and cell-penetrating capability were calculated using ProtParam (http://web.expasy.org/protparam/), peptide property calculator of Innovagen (http://pepcalc.com/), Aggrescan (http://bioinf.uab.es/ aap/), IEDB (http://tools.iedb.org/bcell/) and CellPPD (http://crdd. osdd.net/raghava/cellppd/) web tools. In parallel, the improved peptides were also docked with IFNAR1 to evaluate their IFNAR1-binding affinity.
Molecular dynamics (MD) simulations
MD simulations were performed using GROMACS package version 5 (Pronk et al., 2013) . The 3D structure of initial peptides, MSPEP27, SYR6 and IFNβ in complex with IFNAR1 were solvated in a solvation box with 10.5 Å distance between the edges of the box and the protein fragments. Na + and Cl − ions were added into the box to neutralize the system. Subsequently, the entire systems were minimized and equilibrated for 100 ps using canonical (NVT) and the isothermal-isobaric (NPT) ensembles. Then, the systems were subjected to a 30 ns MD simulation using the leap-frog algorithm with an integration time step of 0.002 ps.
2.1.7. Energetic analyses An average structure was prepared for each peptide-IFNAR1 and IFNβ-IFNAR1 complexes from the last 3 ns MD simulations and subjected to the PRODIGY web tool for calculating the ΔG of interactions as well as determining their polar and nonpolar contacts (Vangone and Bonvin, 2015) . This server calculates the number of interfacial contacts (ICs) and the percentage of non-interacting surface (NIS) in a proteinprotein complex which has been shown to be crucial in physical protein-protein interactions. In parallel, the electrostatic energies were calculated using the PBEQ-Solver tool utilizing 31 snapshot configurations taken from the last 3 ns MD productions of the peptide-IFNAR1 complexes and subsequently averaging the values (Poorebrahim et al., 2017) . The van der Waals (VdW) energies were calculated using a standard GROMACS utility.
Intrinsic fluorescence measurements
Fluorescence measurements were performed using an RF-5000 Shimadzu spectrofluorimeter with a cell compartment thermostated at 293 K. Protein intrinsic fluorescence experiments were carried out at constant IFNAR1 concentration titrated with different MSPEP27 concentrations, to reach a maximum molar ratio of MSPEP27-IFNAR1 equal to 10. The concentration of IFNAR1 was 3 μM and the concentrations of MSPEP27 were from 0 to 30 μM to reach the 10 M ratio of [MSPEP27]/ [IFNβ] . Emission spectra were recorded from 310 to 450 nm with an excitation wavelength of 280 nm and at a scan rate of 60 nm/min. The results of all measurements of fluorescence were corrected by the results of the same titrations of medium without IFNAR1. Spectral resolution was 5 nm for both excitation and emission. In these experiments, 1.0 ml solution with a fixed concentration of MSPEP27 was accurately added into the quartz cell with a 1 cm path length and was manually titrated by successive additions of MSPEP27 at 5 min time intervals. The fluorescence emission spectra were then measured, and the maximum fluorescence intensity (about 340 nm) was used to calculate the binding constant parameters. The binding constant (K a ) and the number of binding (n) were calculated according to the following equation in Section 2.2.8 (Mehraban et al., 2013) :
where F 0 and F are the fluorescence emission intensities of IFNAR1 in the absence and presence of the MSPEP27, respectively, [P] is MSPEP27 concentration, K a is the binding constant, and n is the apparent molar
2.1.9. Visual presentations All peptide and protein structures were depicted using PyMOL and UCSF chimera programs (Pettersen et al., 2004) . The graphs resulted from analysis of MD simulation trajectories were plotted using the Grace software (GRACE: http://plasma-gate.weizmann.ac.il/Grace/).
In vivo validations
Animals and EAE induction
Naive, C57BL/6 mice (male, 8 weeks old, 20-25 g weight, purchased from Pasteur Institute, Karaj, Iran) were housed with a 12-h light/dark cycle with access to water and food ad libitum in specific pathogen-free conditions. The animal experiments were carried out according to the protocols approved by the university of Zabol animal care and use committee. In EAE group mice were anesthetized with isoflurane and subcutaneously injected with 250 μg (100 μl) of MOG35-55 (myelin oligodendrocyte glycoprotein; Alexis Company, Lausanne, Switzerland) 1:1 suspended in 100 μl complete Freund's adjuvant (CFA) into the hind flank. Mice were also intraperitoneally (i.p.) injected with 400 ng of pertussis toxin (Difco Laboratories, Livonia, MI) in 200 μl of phosphate buffered saline (PBS). A second, identical injection of pertussis toxin was given two days following the first immunization. Injections were distributed over four spots (i.e.,~100 μl per site) across the flank areas (Ramroodi et al., 2015 (Tullman, 2013) . As MSPEP27 is a mimetic peptide of IFNβ, we used it with some modifications to better compare with IFNβ. To bypass the blood-brain barrier and other mechanisms that limit systemic drug distribution into the brain, ICVI route of administration was selected for this research to allow CNS entrance of exact concentrations used for both MSPEP27 and IFNβ.
Model characteristic and clinical evaluation
Mice were scored, blinded, as follows: 0, no overt signs of disease; 1, limp tail; 2, limp tail and hind limb weakness; 3, partial hind limb paralysis of one (hemiparesis) or both sides (paraparesis); 4, complete hind limb paralysis of one (hemiplegia) or both sides (paraplegia); 5, moribund state. The day of immunization was considered as EAE day 0 and clinical behavior of mice was scored daily in accordance with the criteria described by Peiris et al. (2007) .
Immunohistochemical (IHC) analysis
On the 21st day of EAE induction in each of the experimental groups, animals were i.p. euthanized using ketamine (50 mg kg − 1 ) and xylazine (4 mg kg − 1 ), followed by cervical dislocation and opening the diaphragm. Thereafter, mice were transcardially perfused with PBS and 4% PFA (paraformaldehyde). Brains were dissected and post-fixed for 24 h in 4% PFA and embedded in paraffin. Fixed brains were coronal sectioned (8 μm), and the cerebral cortex was identified in accordance with the stereotaxic mouse brain atlas and used for staining and IHC analysis. Slides were incubated in blocking solution (PBS containing 2% BSA, 1% normal goat serum and 0.2% Triton X-100), and afterward incubated for 1 h in permeabilization buffer (10% goat serum, 0.1% Triton X-100 in PBS). The sections were subsequently incubated with the appropriate primary antibody (dilution 1:500) at 4°C overnight followed by washing and further incubation with secondary antibodies (dilution 1:1000) for 2 h in antibody solution (5% goat serum, 0.05% Triton X-100 in PBS). Antibodies included; rabbit anti-interleukin-17 (IL-17) polyclonal antibody (Abcam), rat anti-human leukocyte adhesion glycoprotein Mac-1α (CD11b) monoclonal antibody (Santa Cruz), and mouse anti-lymphocyte common antigen (CD45) monoclonal antibody (Santa Cruz). Secondary antibodies for visualization included goat anti-rat monoclonal antibodies conjugated with Alexa Fluor 488 and goat anti-rabbit/mouse monoclonal antibodies conjugated with Alexa Fluor 555. Negative controls were obtained by omitting either the primary or secondary antibody and gave no signal (data not shown). Cell nuclei were counterstained with DAPI for the analysis of total cellular infiltration. Slides were examined using a fluorescence microscope (Olympus IX71), and images were captured at a magnification of × 400 using an Olympus digital camera. The contrast and brightness of images were adjusted using Adobe Photoshop CS5 software (Adobe Systems Inc., San Jose, CA). Subsequently, images were quantified using NIH (National Institute of Health) ImageJ software (Bethesda, MD) (Solati Sarvandi et al., 2015) .
RNA extraction and cDNA synthesis
At the 21st day of EAE induction, animals were euthanized as described in the previous section. Thereafter, mice were transcardially perfused with PBS, the brains were dissected, cerebral cortex was isolated and snap-frozen in liquid nitrogen. The total RNA was isolated from frozen tissue homogenates using a RNeasy Mini Kit (Qiagen, Germany). The purity and concentration of the extracted RNA were determined by Nanodrop 1000 (Thermo-Scientific, USA). The cDNA was transcribed from one microgram of the total RNA using a PrimeScript™ 1st strand cDNA synthesis kit (Takara, Japan) according to the manufacturer's instruction.
Quantitative real-time PCR
The mRNA levels of the target genes including; matrix metalloproteinase 2 and 9 (MMP2 and MMP9), tissue inhibitor of matrix metalloproteinase (TIMP-1) and hypoxanthine Phosphoribosyl transferase 1 (HPRT-1), as a normalizer, were measured by quantitative real-time PCR (qRT-PCR) using a step-one system (Applied Biosystems, USA). The sequence of specific primers used for measurement of MMP2, MMP9, TIMP-1, and HPRT1 levels as well as length of amplified fragments were as follows: HPRT1 (5′-CAGCGTCGTGATTAGTGA-3′ and 5′-GGTCAGC AAAGAACTTATAGC-3′, 215 bp), MMP2 (5′-GACGCTGCCTTTAACTGG AGT-3′ and 5′-TCCAGGTTATCAGGGATGGCA-3′, 270 bp), MMP9 (5′-CCTGGAACTCACACAACGTCT-3′ and 5′-GCAGGAGGTCATAGGTC ACG-3′, 135 bp), and TIMP-1 (5′-CTATAGTGCTGGCTGTGGGGT-3′ and 5′-CAGGCAAAGTGATCGCTCTGG-3′, 365 bp). All PCR amplifications were performed in duplicate reactions utilizing 0.2 μl volume microtubes. The reaction mixture comprised of 5 pmol of specific primers, and 10 μl of Master Mix SYBR Green (2 × qPCR Master Mix with SYBR Green I and Rox) in a total volume of 20 μl. The PCR protocol was accomplished as follows: an initial melting step at 95°C for 10 min to activate DNA Taq polymerase, 40 two-step cycles with 15 s at 95°C for denaturation followed by annealing and extension at 60°C for 1 min. The melting curve was tested to ensure the specificity of PCR products. To determine the relative quantification of gene expression, mean Ct value for each duplicate measurement were used using 2 − ΔΔC (Mard et al., 2014) .
Estimation of circulating inflammatory biomarkers
At the 21st day of EAE induction, animals were euthanized as described earlier. Thereafter, blood obtained via cardiac puncture and plasma was prepared. Expression levels of tumor necrosis factor-alpha (TNFα) and interleukin 1β (IL1β) were measured in the plasma using commercially available quantitative enzyme-linked immunosorbent assay (ELISA) kits (R&D Systems Europe, Abingdon, UK). The cytokine concentrations of respective samples were quantified by standard curves prepared by recombinant cytokines of known concentrations (Sanadgol et al., 2012) . Samples were quantified only if the absorbance fell on the linear portion of the standard curve. Each sample was run in triplicate.
Statistics
For quantitative measurement, the groups were analyzed using oneway analysis of variance (ANOVA) or the unpaired t-test. A Bonferroni post hoc test for multiple group comparisons was used when appropriate. Each experiment was repeated at least three times and the results were considered significant at P < 0.05.
Results
In silico results
3.1.1. Sequence 83-109 of IFNβ was considered for rational peptide design Several highly conserved regions were determined in the sequence of IFNβ after performing a multiple sequence alignment between human, mouse and rat IFNβ. However, the most conserved region is located from amino acids 83 to 109 of the human IFNβ sequence (Fig. 1A) . Sequence alignment of this region in human, mouse and rat revealed 70.37% identity and 85.18% similarity between these species. Surprisingly, a sequence alignment of IFNβ and SYR6 deciphered that the peptide SYR6 had a significant similarity to the sequence 95-109 of IFNβ, precisely within the candidate site (Fig. 1B) . As SYR6 has been reported as a peptide mimetic of IFNβ with anti-viral activity, the chosen conserved region may presumably play a crucial role in biological activity of IFNβ. Further functional studies utilizing the ConSurf web tool revealed that the selected region comprises several functionally and structurally conserved residues that are expected to have a central role in IFNβ-IFNAR1 interactions ( Fig. 2A) . Structural assignments of IFNβ illustrated that the candidate site encompasses a side of the protein that is built up by α-helices 4, 5 and 6, and two loop spacers (Fig. 2B) . Interestingly, detailed interpretation of murine Ifnar1 in complex with Ifnβ using PDBsum and Ligplot + tools revealed that the residues of the chosen region are apparently involved in the binding of Ifnβ to Ifnar1 (Laskowski, 2001 ). The murine Ifnβ-Ifnar1 complex, along with regions of Ifnβ which are involved in binding to Ifnar1, is depicted in Fig. 2C . This finding was also corroborated by a blind docking between human IFNβ and IFNAR1 (Fig. 2D) .
Superimposition of alpha-carbon backbones of murine Ifnar1 and human IFNAR1 (RMSD = 2.63 Å) as well as murine Ifnβ and human IFNβ (RMSD = 2.06 Å) demonstrated that there is a notable structural similarity between the proteins of murine and human implying the similarity in their interaction mode (Fig. 3A, B) . Consequently, the predominant binding sites obtained from published crystallography data (PDB ID: 3WCY) as well as computational docking information were integrated for conducting a high-resolution docking between human IFNβ and IFNAR1. The binding site of IFNβ is located between α-helix 4 and α-helix 6 of the protein, whereas the main Ifnβ-binding site of Ifnar1 is between SD2 and SD3 (Fig. 3C, D) . Following prediction of 3D structures of the initial peptide (MLQNGRALRKQNFLNTGLRKL-GHENLL) and MSPEP27 (MLQNGRDVRKRGFSDTGLRKLGRVNLL) by PEP-FOLD (Fig. 3E) , a high-resolution docking was performed between each peptide and IFNAR1. The solution structure of SYR6 peptide was downloaded from PDB (PDB ID: 1ID7) and docked with IFNAR1. 
MSPEP27 is precisely bound to IFNβ-binding site of IFNAR1
The in silico assessments revealed that MSPEP27 is most likely capable of binding to IFNAR1, with approximately similar binding energy compared to IFNβ. The K d of MSPEP27 is, however, four orders of magnitude higher than that of IFNβ. Similar to IFNβ, calculation of nonbonded connections implicated important roles of electrostatic energies in the interaction selectivity of the peptides with IFNAR1. The initial and SYR6 peptides appear to have less IFNAR1-binding affinity than MSPEP27 (Table 1) .
Calculation of surface electrostatic potential demonstrated the main binding sites of IFNAR1 and IFNβ have two distinct positively-and negatively-charged interfaces (Fig. 4A, B) . This feature facilitates the binding of IFNβ to its receptor. Considering that the majority of IFNAR1 interacting residues (residues 118-136) make negative surface potential, we considered the high positive surface potential as an important criterion for designing IFNβ mimetic peptide. However, there is a negative surface potential in MSPEP27 to interact with positivelycharged residues of binding interface of IFNAR1. Moreover, accessible surface area of MSPEP27 (2967.712 Å 2 ) appeared to be higher than initial peptide (2912.525 Å 2 ) postulating its major binding affinity to IFNAR1 (Fig. 4C) .
All examined peptides could precisely bind to the determined binding site of IFNAR1 in silico, between SD2 and SD3 (Fig. 5) . The number of interfacial contacts (ICs), particularly polar-apolar and charged-polar contacts, between MSPEP27 and IFNAR1 was substantially higher than the initial peptide and SYR6. Total number of connections in MSPEP27-IFNAR1 (62 contacts) were obviously higher than initial peptide-IFNAR1 (49 contacts) and SYR6-IFNAR1 (42 contacts) complexes implicating that MSPEP27 may probably form a stable interaction compared to other studied peptides. The high number of charged-apolar contacts between all studied peptides and IFNAR1 implicate the pivotal role of these interactions in IFNAR1 signaling. 
Physicochemical properties of MSPEP27
Calculation of the physicochemical properties of the initial peptide revealed some undesirable features. Thus, several properties of this peptide were improved using some logical amino acid substitutions to derive MSPEP27. The net charge of MSPEP27 at pH 7 (+5) is close to that of IFNβ (+4.3). Moreover, MSPEP27 has a significantly higher theoretical pI compared to IFNβ, mostly attributable to an increase in arginine and lysine residues. Importantly, the lower values of the instability index and GRAVY of MSPEP27 (instability index = 20.34, GRAVY = − 0.696) compared to IFNβ (instability index = 49.23, GRAVY = − 0.427) postulate that the peptide has higher stability and hydrophilicity than IFNβ. In contrast to IFNβ, the MSPEP27 sequence showed an absence of aggregation hot spots implying that the bioactivity of the peptide may not be limited due to aggregation. Table 2 summarizes measured physicochemical properties of the peptides and IFNβ.
The dynamics properties of peptide-IFNAR1 complexes
Conformational changes of the peptide-IFNAR1 complexes as well as IFNβ-IFNAR1 were assessed using plotted root mean square deviation (RMSD) of the backbone atoms and radius of gyration (Rg). RMSD and Rg values are widely used for evaluating macromolecules stability and rigidity, respectively (Simmerling et al., 2002; Lobanov et al., 2008) . Very small (~0.25 nm at the first 15-ns and~0.3 nm in the second 15-ns of MD simulations) and invariable RMSD values of the MSPEP27-IFNAR1 complex imply a high stability and low conformational freedom of the peptide-receptor complex during MD simulations. In contrast, RMSD of SYR6 complexes exhibited some structural fluctuations upon binding to IFNAR1 that can be fully attributed to their structure (Fig. 6A ). Except for a short period, the Rg of MSPEP27 remained approximately 1.95 nm over the 30 ns MD simulations. The Rg of IFNβ increased to~2.3 nm, then decreased to stabilized at 2.25 nm. The Rg values of SYR6-IFNAR1 exhibited a sharp increase from~2 nm to~2.05 nm at 20 ns, and then stabilize around this value (Fig. 6B) . The initial peptide attained a significant distance from IFNAR1 during MD production phase, and therefore was omitted from analyses.
Intriguingly, using an averaged configuration of MSPEP27-IFNAR1 complex during MD simulations, the content of α-helix in MSPEP27 was shown to increase upon binding to IFNAR1 (77%) compared to unbound MSPEP27 (73%). This conformational change of MSPEP27 results in a stable interaction of MSPEP27 with IFNAR1.
MSPEP27 could strongly bind to IFNAR1
For biomacromolecules, such as proteins, fluorescence measurements could provide useful information including the binding of molecules to proteins at the molecular level. When physicochemical conditions of local surroundings of IFNAR1 are changed slightly, its intrinsic fluorescence would become significantly weakened, where some factors such as biomolecule binding could be responsible for the weakening. To determine the quenching mechanism of the interaction between IFNAR1 and the MSPEP27, the fluorescence studies were carried out at 298 K (Fig. 7) . As can be seen in Fig. 7A, IFNAR1 fluorescence intensity quenched remarkably as MSPEP27 concentrations increased. This trend indicated that MSPEP27 could interact with IFNAR1, implying the formation of MSPEP27-IFNAR1 inclusion complexes. The reduction in fluorescence intensity resulted from the diminution of the fluorescence quantum yield, which in turn was the result of a lowering of the electronic density after the peptide molecule interacted the receptor. This interaction caused the changes in the microenvironment of aromatic fluorophores of the receptor. This interaction caused the changes in the microenvironment of aromatic fluorophores of the receptor.
Fluorescence quenching data from the interaction of the peptide and receptor were analyzed to obtain various binding parameters. The possible number of binding sites n and binding constant K a can be determined by using Eq. (1). A plot of log [(F 0 -F)/F] versus log [P] (Fig. 7B) gives a straight line, and the slope equals to n, and the intercept on Y-axis equals to log K a . The values of K a and n at 298 K were 3.67( ± 0.24) × 10 7 M − 1 and 1.17( ± 0.09), respectively. The n and K a values indicated that IFNAR1 significantly interacts with the peptide, forming equimolar complex. It is evident from K a value that the binding of the peptide and receptor is enough strong to make a peptide-receptor inclusion complex.
In vivo validations
3.2.1. Therapeutic effects of MSPEP27 treatment on the development of progressive EAE We surveyed whether MSPEP27 (10, 20 mg kg − 1 , i.v.) in day 14 has a therapeutic effect in the EAE model. Mice were typically observed for 3 weeks, during which mice remained chronically paralyzed with onset of paralysis between 12 and 16 days after immunization, and maximum score of 3 to 4 in most mice. Typical EAE onset observed 8 to 11 days after immunization, with peak of disease 12 to 17 days after onset for each mouse. MSPEP27 treatment significantly attenuated severity of clinical EAE compared to the vehicle group (P ˂ 0.05 and P ˂ 0.01). Our results showed that area under curve (AUC) in MSPEP27-treated groups showed a higher decrease as compared with EAE group (Fig. 8) . Therefore, mice treated with MSPEP27 showed a significant reduction in the clinical score in comparison with vehicle group, indicating that MSPEP27 has a modulatory effect on EAE progression (Fig. 8) . As expected, mice treated with IFNβ (10 or 20 mg kg − 1 , i.v.) showed a significant reduction in the clinical score in comparison with EAE groups. There was no statistically significant difference between effects of MSPEP27 and IFNβ on changes in clinical scores during treatments ( Fig. 8A, B) . Accordingly, a significant amelioration in clinical severity was observed for both IFNβ-and MSPEP27-injected groups in a timedependent manner. Moreover, raising the dose of MSPEP27 could further protect mice from EAE clinical symptoms. Indeed, our data indicate that an increased in drug dosage for both IFNβ and MSPEP27 improves disease protection with approximately same pattern.
Change in expression pattern of MMP2, MMP9, TIMP-1, IL1β and TNFα after MSPEP27 treatment
To test the MSPEP27 response over the course of the EAE treatment, protein and gene expression of some related genes such as MMP2, MMP9, TIMP-1, IL1β and TNFα were monitored and compared with IFNβ response at the end of the experiment. Treatment with both higher doses (20 mg kg − 1 ) of MSPEP27 and IFNβ showed a significant decrease in MMP2 and MMP9 gene expression in the brain tissue compared to the vehicle group (P ˂ 0.05) (Fig. 9A, B) . In addition, treatment groups with higher doses showed a significant increase in the TIMP-1 gene expression compared to vehicle group (P ˂ 0.05) (Fig. 9C) . After treatment with different concentrations of IFNβ and MSPEP27, EAE mice showed a significant decrease in plasma levels of TNFα and IL1β compared to vehicle group (P ˂ 0.05) (Fig. 9D, E) . However, the reduction of these inflammation mediators was more pronounced in IFNβ-treated mice.
3.2.3. Significant reduction of IL-17, CD11b, and CD45 in the cerebral cortex after MSPEP27 treatment To assessment of inflammatory infiltrates and monitoring brain inflammation, IHC staining for IL-17 as the most important pro-inflammatory cytokine produced by T-helper cells, CD11b as an activated macrophages and microglia marker, and CD45 as a general leukocytes marker were performed. According to the results, IL-17, CD11b, and CD45 positive cells were considerably decreased in mice treated with MSPEP27, particularly in the higher dosage (20 mg kg
). Quantitative analysis revealed that this reduction occurs in a dose-dependent manner. The percentage of IL-17, CD11b and CD45 positive cells in the mice treated with 20 mg kg − 1 of MSPEP27, were all less than half of the untreated EAE mice. In this appraisal, the most significant decrease was observed for CD45, especially when 20 mg kg − 1 of MSPEP27 was applied (Fig. 10A) . On the other hand, IL-17, CD11b, and CD45 positive cells were considerably decreased in mice treated with IFNβ, particularly in the 20 mg kg − 1 dosage (Fig. 10B ). There was no statistically significant difference between effects of MSPEP27 and IFNβ on expression of IL-17, CD11b, and CD45 during treatments ( Fig. 10A and B) . 
Discussions and conclusions
Discussions
IFNβ-based drugs have revolutionized the treatment of MS by demonstrating a clinically significant decrease in disease progression, reduction of frequency of MS attacks and the number of new lesions that can be detected by magnetic resonance imaging (MRI). These effects presumably occur through the activation of signaling pathways downstream of IFNAR. However, consequences of neutralizing antibody (NAbs) formation against IFNβ-based therapies for MS has been a topic of debate for several years (Cohen et al., 2008) . In this study, a novel peptide, called MSPEP27, was designed and developed as a mimetic of human IFNβ, for the treatment of MS. It is plausible that this peptide can efficiently modulate the detrimental inflammation mediating the demyelination process. Based on the results of MD simulations, formation of a stable MSPEP27-IFNAR1 complex implies the high potential of MSPEP27 to compete with IFNβ for binding to IFNAR1. Consequently, this peptide may also be able to induce a conformational change in IFNAR1 structure required for elicitation of downstream response. Thus, the immunomodulatory effect of MSPEP27 in the EAE model can be attributed to its excellent binding affinity to IFNAR1. Due to its smaller size and better physicochemical properties, however, it can be postulated that the side effects of MSPEP27 therapy will be much lower than that of IFNβ. It should be emphasized that further experiments are necessary to determine the favorable dose and administration route.
Owing to their unique physicochemical properties, peptides have found increasing applications in important branches of biological and medical researches. These small compounds are highly selective, efficacious, safe and stable (Fosgerau and Hoffmann, 2015) . Therefore, peptides/peptidomimetics are now widely used in immunomodulation of several autoimmune diseases such as MS, rheumatoid arthritis, systemic lupus as well as HIV infections and cancers (Gokhale and Satyanarayanajois, 2014) . Herein, this approach was used for the treatment of MS to avoid side effects and the intrinsic weaknesses of all IFNβ formulations. Like IFNβ, MSPEP27 was capable of reducing the expression of crucial inflammatory factors. We suppose that this antiinflammatory effect of MSPEP27 is mediated through stable interaction of the peptide with IFNAR1. This claim was confirmed using MD simulation that is reliably used for understanding the physical basis of structure-function of macromolecules under physiological conditions (Karplus and McCammon, 2002) . Owing to its smaller size and lack of epitopes, it is reasonable that the activity of MSPEP27 is not limited via production of neutralizing antibodies. This is because of the fact that antibodies usually bind to the native protein with higher affinity than the peptides. However, some controversies have been reported for a number of peptides with stable structures such as cyclized peptides (Camacho et al., 2008) . The linear MSPEP27 does not seem to have a stable structure, similar to IFNβ, to elicit neutralizing antibodies. This was further proved by dynamic changes of MSPEP27 conformation during MD simulation. The lower values of the instability index and GRAVY of MSPEP27 implicate the higher stability and hydrophilicity level of the peptide which may translate to longer bioactivity when compared to IFNβ. The instability index is measured according to the occurrence of certain dipeptides in a protein sequence. It is now well documented that the occurrence frequency of certain dipeptides is significantly different in the unstable proteins compared to those in the stable ones. Accordingly, instability index values below 40 imply an unstable structure of the assessed protein or peptide (Guruprasad et al., 1990) . The instability index of MSPEP27 and IFNβ was calculated as 24.17 and 49.23, respectively. Positive GRAVY values infer that the protein or peptide is hydrophobic, while a negative GRAVY value shows the hydrophilicity of a protein (Kyte and Doolittle, 1982) . Both MSPEP27 and IFNβ demonstrated a negative GRAVY value implying their desire activity in hydrophilic conditions. Unraveling the aggregation hotspots and epitopes on protein surfaces has become an increasingly important factor in designing protein-based drugs (PelayGimeno et al., 2015) . These regions can potentially increase the immunogenicity and reduce the half-life and activity of protein-based drugs. Prediction of aggregation hot spots and epitopes illustrated that IFNβ-based design of MSPEP27 had reduced the aggregation hot spots (7 numbers) and antigenic regions (6 numbers) of the peptide to zero.
MMPs are a class of zinc-dependent endopeptidases involved in an array of physiological processes including remodeling of extracellular matrix (ECM), angiogenesis and cytokine regulation. The enzymatic activity of these proteins is precisely regulated by TIMPs, a group of inhibitor proteins consisting of four family members. Studies have shown that up-regulation of MMPs is substantially associated with an increased number of gadolinium-enhancing MRI lesions (Vincenti, 2001) . In particular, expression of MMP9 has been demonstrated to be elevated around plaques and reaches highest levels during the appearance of clinical symptoms. Furthermore, enhanced MMP2 expression results in chronic progression of MS (Avolio et al., 2003; Kieseier et al., 1998) . In contrast, serum levels of TIMP-1 are significantly lower in RRMS patients than normal matched controls (Boz et al., 2006) . Recent studies have found that IFNβ, a commonly used immunomodulatory agent in MS, can efficiently reduce production of MMP9 by T cells, and thereby decrease transmigration of T lymphocytes across basement membrane barrier (Yushchenko et al., 2003) .
However, TIMP-1 levels have shown to be gradually increased during IFNβ-based therapy (Karabudak et al., 2004) . The modulatory effect of IFNβ on the gelatinolytic activities of MMP2 and MMP9 has also reported by Kurzepa and Stryjecka-Zimmer (2007) . Furthermore, IL1β and TNFα are crucial mediators of inflammatory reactions in the CNS of MS patients (Heidary et al., 2014; Lim and Constantinescu, 2010) . On the other hand, biopsies from MS patients taken for diagnostic reasons showed that cortical demyelination is already present at early stages of the disease and, when this happens, the lesions show profound lymphocytic infiltration similar to that seen in active white matter lesions (Lucchinetti et al., 2011) . EAE is composed of an induction phase, which involves the loading of myelin specific T cells following immunization with myelin individual proteins, and an effector phase, which involves the migration of activated myelin-specific T cells to the CNS and triggering of neuroinflammation (Ramroodi et al., 2015) . Since, in MOG-induced EAE both spinal cord and forebrain regions are attacked simultaneously (Girolamo et al., 2011) , in this experiment we evaluated cerebral cortex region in C57BL/6 mice by focusing on inflammatory responses, and trans-endothelium migration of immune cells.
In agreement with previous findings, analysis of cerebral cortex in EAE mice revealed that treatment with both MSPEP27 and IFNβ significantly decreased mRNA expression of MMP2 and MMP9 and protein concentration of IL1β and TNFα in compare with EAE group.
Interpretation of IHC on the cerebral cortex of EAE mice revealed that the groups treated with MSPEP27 were remarkably different from the untreated vehicle group in a number of cells presenting IL17, CD11b, and CD45. A remarkable and significant decrease was observed in the expression of all three aforementioned proteins after treatment with both MSPEP27 and IFNβ. Furthermore, we noticed that this reduction was dose-dependent and that 20 mg kg − 1 of the peptide could attenuate the expression of these markers more efficiently than 10 mg kg
. IL17 is a cytokine that is produced by activated T cells which are differentiated to Th17 cells and have been implicated in the pathogenesis of neuroinflammatory diseases (Constantinescu et al., 2011) . Durelli and colleagues have been reported that the percentage of Th17 cells in patient with active MS was sevenfold more than healthy subjects and IFNβ treatment could reduce the number of these cells (Durelli et al., 2009) . Likewise, MSPEP27 treatment successfully reduced the number of IL17 expressing cells in our experiment. Moreover, it is also established that the expression of CD11b on monocytes/ macrophages and other pathogenic cells is essential for EAE creating (Bullard et al., 2005) . Our results indicated a significant decrease in the number of CD11b presenting cells (infiltrating macrophage or resident microglia) in the MSPEP27-treated groups compared to the EAE group. Since CD45 is a marker of inflammatory cells, including leukocytes, macrophages and T lymphocytes, the effect of MSPEP27 on expression of this cell marker was also evaluated. Surprisingly, MSPEP27 treatment could significantly reduce CD45 expression in comparison with EAE group.
It has been accepted that IFNβ exerts its therapeutic function in part through anti-proliferative, anti-viral, and particularly, immunomodulatory actions (Kasper and Reder, 2014) . Moreover, intrastriatal injection of IFNβ has been shown to preserve the BBB integrity, block the infiltration of inflammatory cells, and decrease infarct size in a middle cerebral artery occlusion model (Veldhuis et al., 2003) . Furthermore, in a model of transient focal stroke, it was reported that intravenous tail injections of IFNβ failed to provide protection. It appears that IFNβ is unable to cross BBB; thus, methods to circumvent the BBB are needed in order for IFNβ to be effective (Maier et al., 2006) . Although, IFNβ is unable to cross BBB, permeability of BBB to MSPEP27 and possibility of MSPEP27 action within the CNS after systemic administration should be evaluated for either an "in vitro" study using an artificial model of the BBB or the "in vivo" studies in an animal model of MS in the near future.
To address whether MSPEP27 can effectively reduce the undesirable side effects of IFNβ in the body, the subsequent experiments should be performed in future investigations. Assessing the biological half-life of the MSPEP27 versus IFNβ in mice, assessing any potential of MSPEP27 versus IFNβ to generate neutralizing antibodies, determining if leukopenia was less severe after treatment with MSPEP27 versus IFNβ, and determining the long-term potency of the MSPEP27 versus IFNβ beyond 21 days could be supportive of our recent findings. Also the idea being greater potency if the MSPEP27 could decrease the number of injections required to maintain the suppressive phenotype in MS. One of the disadvantages of IFNβ therapies is the need for parenteral therapy. Thus it would be supportive that know whether MSPEP27 can work orally, or, at least, by a less invasive delivery route such as subcutaneous or intraperitoneal delivery.
Conclusions
In conclusion, to the best of our knowledge, this is the first study reporting the rational design of an IFNβ mimetic peptide, called MSPEP27, for application in MS therapy. When compared to IFNβ, MSPEP27 showed relatively similar biological effects on the suppression of inflammatory factors. The oral bioavailability and BBB permeability of this peptide need to be investigated further. Moreover, validation of in silico predictions (e.g., physicochemical properties of MSPEP27) by experimental assays would definitely increase the reliability of this study. Unfortunately, due to some limitations, we could not perform further experiments in this study. However, the results of this study suggest that our peptide-based approach can be considered as an alternative strategy for treatment of MS and most likely to overcome some of the adverse effects associated with IFNβ-based therapies.
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